TME Pharma N.V.
PAR: ALTME.PA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Diede van den Ouden
- Employees
- 12
- Headquarters
- Berlin, Germany
- IPO year
- 2016
- Market cap
- €7.5M
- Website
- https://www.tmepharma.com
Loading ALTME…
Loading profile data…Frequently asked questions about ALTME
What does TME Pharma N.V. (ALTME.PA) do?
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy...
Where does ALTME.PA trade?
TME Pharma N.V. (ALTME.PA) trades on the Euronext Paris.
What sector is ALTME.PA in?
TME Pharma N.V. (ALTME.PA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of TME Pharma N.V.?
Diede van den Ouden is the chief executive officer of TME Pharma N.V. (ALTME.PA).
Where is TME Pharma N.V. headquartered?
TME Pharma N.V. is headquartered in Germany.
Does ALTME.PA pay a dividend?
TME Pharma N.V. (ALTME.PA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ALTME.PA go public?
TME Pharma N.V. (ALTME.PA) completed its initial public offering in 2016.